FDA Panel Calls for Warning Labels on Gadolinium FDA Panel Calls for Warning Labels on Gadolinium

An FDA advisory committee voted 13 to 1, with 1 abstention, to recommend safety labeling changes for gadolinium-based contrast agents used during MRI.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news